Johannes Gutenberg-Universität Mainz
- 6131/39-0
Geschke, Katharina; Palm, Svenja; Fellgiebel, Andreas et al.
Resilience in Informal Caregivers of People Living with Dementia in the Face of COVID-19 Pandemic-Related Changes to Daily Life A Narrative ReviewGEROPSYCH-THE JOURNAL OF GERONTOPSYCHOLOGY AND GERIATRIC PSYCHIATRY. Bd. 35. H. 1. 2021 S. 30-41
Helmreich, I; Tüscher, O; Gilan, D et al.
Resilienzforschung und Prävention - Das Leibniz-Institut für Resilienzforschung in Mainz. [Resilience research and prevention - The Leibniz Institute for Resilience Research in Mainz.]Nervenheilkunde. Bd. 40. H. 04. 2021 S. 229-235
Ascher, Stefanie; Wilms, Eivor; Pontarollo, Giulia et al.
Response by Ascher et al to Letter Regarding Article, "Gut Microbiota Restricts NETosis in Acute Mesenteric Ischemia-Reperfusion Injury"ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. Bd. 41. H. 1. 2021 S. E74-E75
Stege, H. M.; Haist, M.; Schultheis, S. et al.
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG studyCANCER IMMUNOLOGY IMMUNOTHERAPY. Bd. 70. H. 11. 2021 S. 3313-3322
Kahaly, George J.; Bartalena, Luigi
Response to comment by Smith on the 2021 EUGOGO guidelinesEUROPEAN JOURNAL OF ENDOCRINOLOGY. Bd. 185. H. 6. 2021 S. L15-L16
Lang, Hauke; Kloth, Michael; Moehler, Markus et al.
Response to the Comment on "Extended Molecular Profiling Improves Stratification and Prediction of Survival After Resection of Colorectal Liver Metastases''ANNALS OF SURGERY. Bd. 274. H. 6. 2021 S. E714-E714
Dukic, Stefan; McMackin, Roisin; Costello, Emmet et al.
Resting-state EEG reveals four subphenotypes of amyotrophic lateral sclerosisBRAIN. Bd. 145. H. 2. 2021 S. 621-631
Mayer, Philipp; Kraft, Anne; Witzel, Hagen R. et al.
Restricted Water Diffusion in Diffusion-Weighted Magnetic Resonance Imaging in Pancreatic Cancer is Associated with Tumor HypoxiaCANCERS. Bd. 13. H. 1. 2021
Kim, Richard D.; Harris, William P.; Sung, Max W. et al.
Results of a phase Ib study of regorafenib (REG) 80 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 3. 2021
Wiegel, Thomas; Albers, Peter; Bartkowiak, Detlef et al.
Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial) (Sep, 10.1007/s00432-020-03327-2, 2020)JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. Bd. 147. H. 1. 2021 S. 243-244